Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electroc...(re information visitColubris on the Web ...),Health
Navigation Links
Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph
Date:2/25/2008
re information, visit Colubris on the Web at http://www.colubris.com.
MEDIA CONTACTS: Carl Blume Rob Morton
Colubris Networks, Inc. Davies Murphy Group, Inc.
781-547-0325 781-418-2460
cblume@colubris.com colubris@daviesmurphy.com
http://www.colubris.com http://www.daviesmurphy.com
'/>"/>
| SOURCE Colubris Networks Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association
3. Family History Has Strong Effect on Cardiac Risk
4. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
5. Cardiac Science to Present at the UBS Global Life Sciences Conference
6. Cardiac Science Applauds Mass AED Training of Pittsburgh Educators
7. Guidelines help patients reduce risk of cardiac event before surgery
8. Cardiac Science Named to Deloittes Technology Fast 50 for Washington State
9. Cleveland Clinic and The Larry King Cardiac Foundation Partner to Provide Heart Surgery to Those in Need
10. Cardiac Science Releases New Cardiac Rehabilitation System
11. Cardiac Artery Trouble Boosts Family Heart Risk
Post Your Comments:
(Date:7/23/2008)... Dr. Stephen Cohen Hired As New CEO, ATLANTA,...r Group,(GMCG) announced today that MELCO Investme...ment fund, has signed on as a key partner with a,s...the investment, GMCG has,also appointed Dr. Stephe...,surgeons, as its new CEO., (Photo: http://www.n...
(Date:7/23/2008)...d and Medicare Rules Highlighted; a Focus on Preve...tions, LANSING, Mich., July 23 /PRNewswire/ -- Th...&PSI), a national leader in clinical risk manageme... care institutions and,providers, today announced ... conference., The conference will take place Sept...
(Date:7/23/2008)... Michigan Takes Top Honors as the #1 Healthiest Ci...PRNewswire-USNewswire/ -- AARP The Magazine, the,d...largest-circulation,magazine with more than 34 mil...st cities to live and retire in with Ann Arbor, MI...go, ND taking the top five rankings.,Featured in t...
(Date:7/23/2008)...a., July 23 /PRNewswire-USNewswire/ -- The HealthC...m ) today announced that Dr. Fran Cogen,MD, direc...am at Children,s,National Medical Center, will pro...om, a site offering connections to a community of ...priate consultation by a dietician, social,worker,...
Breaking Medicine News(10 mins):Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5Health News:Children's National Medical Center Program Director to Provide Expertise to DiabeTeens.com, The HealthCentral Network's Teen Diabetes Site 2[0] Greater Medical Center Group Receives Major Funding From MELCO Investments[0] The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates[0] AARP the Magazine Names the Top 10 Healthiest Places to Live in America[0] Children's National Medical Center Program Director to Provide Expertise to DiabeTeens.com, The HealthCentral Network's Teen Diabetes Site
... rampant felling of trees for construction purpose...sities in Delhi have raised their voice to save t...e students of Delhi University (DU) have forwarded...eepak Pental objecting to the plan to cut 1,000 tr...
...-enhanced ultrasound (CE-US) after a liver transpl... as biliary complications , according to a recent ... recipients who underwent a CE-US exam after devel...clear liver function tests. "Acute liver failure i...
...vely easy and reliable test is on the cards for pr...ening risks to expectant mothers and their babies...mplication which could kill hundreds of fetuses a ...a test. One in ten pregnancies is fraught with suc...
...niversity researchers seem to know what makes cert...nts. Colleagues from Edinburgh University and the ...losed in on the possible risk factors in premature... expose them to risks of cot death. Professors An...
Other Medicine News:Health News:Students Join Hands to Save Green Cover in Delhi 2Health News:Spit Test Kit on the Cards to Ascertain Pre-eclampsia Risk 2(Date:7/22/2008)...ISBANE, Australia, July 22 /PRNewswire-FirstCall/ ... yesterday, the Board of Progen,Pharmaceuticals Li...t it,had discontinued the PI-88 phase 3 study in l...ion to develop its existing portfolio of compounds...itional compounds and,opportunities through Merger...
(Date:7/22/2008)...test awards under Therapeutics Development Initiat...tions to 23; next deadline January 20,2009, NEW ...f its mission to,speed delivery of transformative ... Michael J. Fox Foundation for Parkinson,s Researc... industry research teams. The awards,were granted ...
(Date:7/22/2008)...te-of-the-Art PET Study Confirms Tyrima Exhibits E...operties - - Results Support Initiation of P..., N.C., July 22 /- CeNeRx BioPharma,...ercializing innovative,treatments for diseases of ...to advance its lead candidate Tyrima(TM) into Phas...
(Date:7/22/2008)...UTH SAN FRANCISCO, Calif., July 22 /-...it has completed patient enrollment,in its Phase 1...lity and,ammonia scavenging effects of HPN-100 (fo...nylbutyrate) in patients with urea cycle disorders...ults in the fourth quarter,of this year., (Logo: ...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 1GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 2GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 3Highlights of Economic and Business Growth in the Tampa Bay Region 800 1Highlights of Economic and Business Growth in the Tampa Bay Region 800 2Highlights of Economic and Business Growth in the Tampa Bay Region 800 3Highlights of Economic and Business Growth in the Tampa Bay Region 800 4Poll reveals public awareness of nanotech stuck at low level 1936 1Poll reveals public awareness of nanotech stuck at low level 1936 2Poll reveals public awareness of nanotech stuck at low level 1936 3Pelosi 3A Mr President Drop the Partisan Rhetoric Put Down the Veto Pen 1933 1[0] Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A[0] Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics[0] CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study[0] Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
... - Dynogen,Pharmaceuticals, Inc. reported positive...controlled Phase 1b trial of DDP733 for,gastroesop...ed to,demonstrate proof-of-concept for DDP733 as a...dose of DDP733 achieved,statistical significance o...n the number of reflux events and was safe and wel...
... 2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today ...al evaluating the company,s once-daily,anti-HIV dr...vir,DF) 300 mg as a potential treatment for chroni...ry efficacy endpoint. The study shows,that Viread ...ral,drug Hepsera(R) (adefovir dipivoxil) among pat...
Other Medicine Technology:Dynogen Reports Positive Results in Phase 1B GERD Study 2Dynogen Reports Positive Results in Phase 1B GERD Study 3Dynogen Reports Positive Results in Phase 1B GERD Study 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7This stain is a classical hematology stain that requires a longer staining time but produces a very dense coloration. It is used in the staining of peripheral blood smears and bone marrows. The resul
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast.
Albumin reagent is used for the quantitative determination of albumin concentration in human serum.
AST (SGOT) reagent is used for the quantitative determination of aspartate aminotransferase (AST) in human serum.
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |